New Season of I am BIO; plus Hope for Alzheimer's (Redux)

12/20/22 • 22 min

I am BIO will begin a new season of exciting topics on Feb 28. During our hiatus, we are bringing back some of our most popular episodes beginning with “Hope for Alzheimer's.”

Alzheimer’s disease is a heartbreaking diagnosis and tragically there is no cure. But every day, researchers, scientists and the medical community are working to change that. In this episode, we speak with three guests who are fighting to bend the trajectory of Alzheimer’s disease and, in doing so, offering hope for the millions suffering from this devastating illness.

I am BIO will begin a new season of exciting topics on Feb 28. During our hiatus, we are bringing back some of our most popular episodes beginning with “Hope for Alzheimer's.”

Previous Episode

Let’s Get Uncomfortable: Talking About Women’s Health

Talking about women’s health has been a taboo subject for some time, contributing to a lack of innovation in the sector. Still today, many are uncomfortable discussing the topic. Consequently, only 2% of medical products in the pipeline are for women’s health and only 2% of all venture capital dollars go into developing these products. In this episode, we talk with two women in biotech who are trying to change that narrative and infuse more investment in innovations that meet the needs of half the population.

Sabrina Martucci Johnson, CEO
Daré Bioscience

Elizabeth Baily, Managing Director
RH Capital

Next Episode

Antimicrobial Resistance: The Silent Pandemic (Redux)

We are on the precipice of a looming crisis. Antimicrobial resistance (AMR) is the evolution of deadly pathogens like bacteria and fungi to resist all current antimicrobial medicines. In this episode, we talk about how the dwindling supply of new antibiotics is fueling this silent pandemic, and why we need a continued pipeline of new antibiotics to avoid this crisis.

Guests:

Ankit Mahadevia, Spero Therapeutics

Henry Skinner, AMR Action Fund

Mary Dwight, Cystic Fibrosis Foundation